The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and mitigate supply chain vulnerabilities, including collaborating with the private sector to develop and implement programs to assess and incentivize resiliency in manufacturer and hospital purchasing behavior. The paper focuses on generic sterile injectable medicines used in inpatient settings, citing their importance and relative risk of supply disruptions.

Related News Articles

Headline
Baxter has resumed production on all of its 3-liter irrigation and peritoneal dialysis solutions manufacturing lines, the company announced Dec. 5. The company…
Headline
The Food and Drug Administration Dec. 4 announced empty IV bags have been added to its Medical Device Shortages List, and that the shortage is estimated to…
Headline
Baxter Nov. 26 announced new allocation levels for multiple IV product groups and advised customers of a one- to two-week lead time for products to flow…
Headline
Baxter expects to restart a second IV solutions manufacturing line within the next week, the company announced Nov. 7. Along with the first line that resumed…
Headline
Supplies of Mo-99/Tc-99M, which are medical radioisotopes used in procedures to diagnose and detect diseases including heart disease and cancer, are…
Headline
Baxter announced Oct. 31 that it has restarted its North Cove, N.C. facility's highest-throughput IV solutions manufacturing line, which normally accounts for…